New Zealand markets closed

BIIB Jul 2022 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.24000.0000 (0.00%)
At close: 02:22PM EDT
Full screen
Previous close0.2400
Open0.1500
Bid0.0000
Ask0.1500
Strike230.00
Expiry date2022-07-01
Day's range0.1500 - 0.2500
Contract rangeN/A
Volume21
Open interest43
  • Business Wire

    Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

    CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,

  • Zacks

    Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

    Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

  • GlobeNewswire

    European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

    Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA® (dimethyl fumarate). The patent, EP 2 653 873, is directed to treating multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European Medicines Agency (EMA) recommended maintenance dose for TECFIDERA. P